Biased agonism at the parathyroid hormone receptor: A demonstration of functional selectivity in bone metabolism

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 856-865

  Bohinc, B N ^a   Gesty Palmer, D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

arrestin Biased agonism; Bone metabolism; G protein coupled receptor; Parathyroid hormone; Parathyroid hormone receptor type 1

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA ARRESTIN 1; BETA ARRESTIN 2; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARVEDILOL; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE[1-31][27 LEUCINE] AMIDE 22,26 AMIDE; PARATHYROID HORMONE[1-34]; PHOSPHODIESTERASE; PROPRANOLOL; RETINA S ANTIGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CATABOLISM; CELL MEMBRANE; CELL MIGRATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENDOCYTOSIS; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; PROTEIN BLOOD LEVEL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; BONE AND BONES; BONE RESORPTION; HUMANS; HYPERCALCEMIA; HYPERCALCIURIA; LIGANDS; MICE; OSTEOGENESIS; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SIGNAL TRANSDUCTION;

EID: 84862849746     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800959125     Document Type: Article

References (80)

1. Lagerström, M. C. and Schiöth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug. Discov., 2008, 7, 339-357.
2. Fredriksson, R.; Lagerström, M. C.; Lundin, L. -G. and Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharm., 2003, 63, 1256-1272.
3. Römpler, H.; Stäubert, C.; Thor, D.; Schulz, A.; Hofreiter, M. and Schöneberg, T. G. protein-coupled time travel: evolutionary aspects of GPCR research. Mol. Interventions, 2007, 7, 17-25.
4. Drews, J. r. Drug discovery: a historical perspective. Science, 2000, 287, 1960-1964.
5. Kenakin, T. and Miller, L. J. Seven transmembrane receptors as shape shifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharm. Reviews., 2010, 62, 265-304.
6. Karlin, A. On the application of a plausible model of allosteric proteins to the receptor for acetylcholine. J. Theor. Biol., 1967, 16, 306-320.
7. Thron, C. D. On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol. Pharm., 1973, 9, 1-9.
8. Kenakin, T. Receptor conformational induction versus selection: all part of the same energy landscape: Agonists can differentially stabilize multiple active states of receptors. Trends. Pharmacol. Sci., 1996, 17, 190-191.
9. Costa, T. and Herz, A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. USA., 1989, 86, 7321-7325.
10. Samama, P.; Cotecchia, S.; Costa, T. and Lefkowitz, R. J. A mutation-induced activated state of the beta2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem., 1993, 268, 4625-4636.
11. Weiss, J. M.; Morgan, P. H.; Lutz, M. W. and Kenakin, T. P. The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy. J. Theor. Biol., 1996, 181, 381-397.
12. Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB Journal, 2001, 15, 598-611.
13. Maudsley, S.; Martin, B. and Luttrell, L. M. The origins of diversity and specificity in g protein-coupled receptor signaling. Curr. Alzhe. Res., 2005, 314, 485-494.
14. Kenakin, T. Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends. Pharmacol. Sci., 1995, 16, 232-238.
15. Laugwitz, K. L.; Allgeier, A.; Offermanns, S.; Spicher, K.; Van Sande, J.; Dumont, J. E. and Schultz, G. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc. Natl. Acad. Sci. USA., 1996, 93,116-120.
16. Angers, S.; Salahpour, A.; Joly, E.; Hilairet, S.; Chelsky, D.; Dennis, M. and Bouvier, M. Detection of beta2-adrenergicreceptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. USA., 2000, 97, 3684-9.
17. Hay, D. L.; Poyner, D. R. and Sexton, P. M. GPCR modulation by RAMPs. Pharmacol. Therapeut., 2006, 109, 173-197.
18. Foord, S. M. and Marshall, F. H. RAMPs: accessory proteins for seven transmembrane domain receptors. Trends. Pharmacol. Sci., 1999, 20, 184-187.
19. Brady, A. E. and Limbird, L. E. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cellular Signalling, 2002, 14, 297-309.
20. Hall, R. A. and Lefkowitz, R. J. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ. Res., 2002, 91, 672-80.
21. Bockaert, J.; Marin, P.; Dumuis, A. and Fagni, L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Letters, 2003, 546, 65-72.
22. Lefkowitz, R. J. G protein--coupled receptor kinases. Cell, 1993,74, 409-412.
23. Ferguson, S. S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev., 2001, 53, 1-24.
24. Luttrell, L. M.; Ferguson, S. S.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Della Rocca, G. J.; Lin, F.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G. and Lefkowitz, R. J. Beta-arrestindependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science, 1999, 283, 655-61.
25. DeFea, K. A.; Zalevsky, J.; Thoma, M. S.; Dery, O.; Mullins, R. D. and Bunnett, N. W. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell. Biol., 2000, 148, 1267-81.
26. DeWire, S. M.; Ahn, S.; Lefkowitz, R. J. and Shenoy, S. K. Beta-Arrestins and Cell Signaling. Annual Review of Physiology, 2007,69, 483-510.
27. Luttrell, L. M. and Gesty-Palmer, D. Beyond desensitization:physiological relevance of arrestin-dependent signaling. Pharmacol. Rev., 2010, 62, 305-330.
28. Luttrell, L. M.; Roudabush, F. L.; Choy, E. W.; Miller, W. E.; Field, M. E.; Pierce, K. L. and Lefkowitz, R. J. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl. Acad. Sci. USA., 2001, 98, 2449-54.
29. McDonald, P. H.; Chow, C. W.; Miller, W. E.; Laporte, S. A.; Field, M. E.; Lin, F. T.; Davis, R. J. and Lefkowitz, R. J. Betaarrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science, 2000, 290, 1574-7.
30. 2-arrestin2 for ERK1/2 activation. J. Biol. Chem., 2006, 281, 38181-38188.
31. Shenoy, S. K. and Lefkowitz, R. J. Seven-transmembrane receptor signaling through beta-arrestin. Science STKE, 2005, 308, cm10.
32. Azzi, M.; Charest, P. G.; Angers, S.; Rousseau, G.; Kohout, T.; Bouvier, M. and Pineyro, G. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations forG protein-coupled receptors. Proc. Natl. Acad. Sci. USA., 2003, 100, 11406-11411.
33. Gesty-Palmer, D.; Chen, M.; Reiter, E.; Ahn, S.; Nelson, C. D.; Wang, S.; Eckhardt, A. E.; Cowan, C. L.; Spurney, R. F.; Luttrell, L. M. and Lefkowitz, R. J. Distinct beta-arrestin-and G proteindependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem., 2006, 281, 10856-10864.
34. Wei, H.; Ahn, S.; Shenoy, S. K.; Karnik, S. S.; Hunyady, L.; Luttrell, L. M. and Lefkowitz, R. J. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. USA., 2003, 100, 10782-10787.
35. Wisler, J. W.; DeWire, S. M.; Whalen, E. J.; Violin, J. D.; Drake, M. T.; Ahn, S.; Shenoy, S. K. and Lefkowitz, R. J. A unique mechanism of beta-blocker action: Carvedilol stimulates betaarrestin signaling. Proc. Natl. Acad. Sci. USA., 2007, 104, 16657-16662.
36. Kanis, J. A.; Melton, L. J.; Christiansen, C.; Johnston, C. C. and Khaltaev, N. The diagnosis of osteoporosis. J. Bon. Min. Res., 1994, 9, 1137-1141.
37. Caverzasio, J.; Palmer, G.; Suzuki, A. and Bonjour, J. Mechanism of the mitogenic effect of fluoride on osteoblast-like cells: Evidences for a G protein-dependent tyrosine phosphorylation process. J. Bon. Min. Res., 1997, 12, 1975-1983.
38. Lau, K. H. W. and David, J. B. Molecular mechanism of action of fluoride on bone cells. J. Bon. Min. Res., 1998, 13, 1660-1667.
39. Vestergaard, P.; Jorgensen, N.; Schwarz, P. and Mosekilde, L. Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis. Osteoporosis International, 2008,19, 257-268.
40. Giustina, A.; Mazziotti, G. and Canalis, E. Growth Hormone, Insulin-like growth factors, and the skeleton. End. Rev., 2008, 29,535-559.
41. Sugimoto, T.; Kaji, H.; Nakaoka, D.; Yamauchi, M.; Yano, S.; Sugishita, T.; Baylink, D. J.; Mohan, S. and Chihara, K. Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis. J. Eur. Endocrinol., 2002, 147, 339-348.
42. Quarles, L. D.; Haupt, D. M.; Davidai, G. and Middleton, J. P. Prostaglandin F2 alpha-induced mitogenesis in MC3T3-E1 osteoblasts: role of protein kinase-C-mediated tyrosine phosphorylation. Endocrinology, 1993, 132, 1505-1513.
43. Soper, D. L.; Milbank, J. B. J.; Mieling, G. E.; Dirr, M. J.; Kende, A. S.; Cooper, R.; Jee, W. S. S.; Yao, W.; Chen, J. L.; Bodman, M.; Lundy, M. W.; De, B.; Stella, M. E.; Ebetino, F. H.; Wang, Y.; deLong, M. A. and Wos, J. A. Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. J. Med. Chem., 2001, 44, 4157-4169.
44. Qin, L.; Raggatt, L. J. and Partridge, N. C. Parathyroid hormone: a double-edged sword for bone metabolism. Tren. Endocrinol. Metabol., 2004, 15, 60-65.
45. Bouxsein, M. L. and Ferrari, S. L. Coupling PTH and arrestins to uncouple bone formation from resorption: A new road to osteoporosis anabolic therapy? IBMS BoneKEy, 2009, 12, 470-476.
46. Ferrari, S. L. and Bouxsein, M. L. Beta-arrestin-biased parathyroid hormone ligands: A new approach to the development of agents that stimulate bone formation. Sci. Trans. Med., 2009, 1, 1ps1-1ps1.
47. Gesty-Palmer, D.; Flannery, P.; Yuan, L.; Corsino, L.; Spurney, R.; Lefkowitz, R. J. and Luttrell, L. M. A beta-arrestin biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Trans. Med.,2009, 1, 1ra1.
48. Dobnig, H. and Turner, R. T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology, 1995, 136, 3632-3638.
49. Schmidt, I.; Dobnig, H. and Turner, R. Intermittent parathyroidhormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology, 1995, 136, 5127-5134.
50. Hock, J. M. and Gera, I. Effects of continuous and intermittent administration and inhibition f resorption on the anabolic response of bone to parathyroid hormone. Journal of Bone and Mineral Research, 1992, 7, 65-72.
51. Ishizuya, T.; Yokose, S.; Hori, M.; Noda, T.; Suda, T.; Yoshiki, S. and Yamaguchi, A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest., 1997, 99, 2961-2970.
52. Tam, C. S.; Heersche, J. N.; Murray, T. M. and Parsons, J. A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 1982, 110, 506-512.
53. Abou-Samra, A. B.; Juppner, H.; Force, T.; Freeman, M. W.; Kong, X. F.; Schipani, E.; Urena, P.; Richards, J.; Bonventre, J. V.; Potts, J. T., Jr. and et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc. Natl.Acad. Sci. USA., 1992, 89, 2732-6.
54. Juppner, H.; Abou-Samra, A. B.; Freeman, M.; Kong, X. F.; Schipani, E.; Richards, J.; Kolakowski, L. F., Jr.; Hock, J.; Potts, J. T., Jr.; Kronenberg, H. M. and et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science, 1991, 254, 1024-1026.
55. Bringhurst, F. R.; Juppner, H.; Guo, J.; Urena, P.; Potts, J. T., Jr.; Kronenberg, H. M.; Abou-Samra, A. B. and Segre, G. V. Cloned, stably expressed parathyroid hormone (PTH)/PTH-related peptide receptors activate multiple messenger signals and biological responses in LLC-PK1 kidney cells. Endocrinology, 1993, 132, 2090-2098.
56. Iida-Klein, A.; Guo, J.; Takemura, M.; Drake, M. T.; Potts, J. T., Jr.; Abou-Samra, A.; Bringhurst, F. R. and Segre, G. V. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTHstimulated phospholipase C activity. J. Biol. Chem., 1997, 272,6882-6889.
57. Koh, A. J.; Beecher, C. A.; Rosol, T. J. and McCauley, L. K. 3',5'- Cyclic adenosine monophosphate activation in osteoblastic cells: Effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology, 1999, 140, 3154-3162.
58. Mahon, M. J.; Cole, J. A.; Lederer, E. D. and Segre, G. V. Na+/H+exchanger-regulatory factor 1 mediates inhibition of phosphate transport by parathyroid hormone and second messengers by actingat multiple sites in opossum kidney cells. Mol. Endo., 2003, 17,2355-2364.
59. Cole, J. A. Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology, 1999, 140,5771-5779.
60. Lederer, E. D.; Sohi, S. S. and McLeish, K. R. Parathyroid hormone stimulates extracellular signal-regulated kinase (ERK) activity through two independent signal transduction pathways: role of ERK in sodium-phosphate cotransport. J. Amer. Soc. Neph.,2000, 11, 222-231.
61. Verheijen, M. H. and Defize, L. H. Parathyroid hormone activates mitogen-activated protein kinase via a cAMP-mediated pathway independent of Ras. J. Biol. Chem., 1997, 272, 3423-3429.
62. Garcia-Ocana, A.; Gomez-Casero, E.; Penaranda, C. and Esbrit, P. Parathyroid hormone-related protein increases DNA synthesis in proximal tubule cells by cyclic AMP-and protein kinase Cdependent pathways. Life Sciences, 1998, 62, 2267-2273.
63. Swarthout, J. T.; Doggett, T. A.; Lemker, J. L. and Partridge, N. C. Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent. J. Biol. Chem., 2001, 276, 7586-7592.
64. Ferrari, S. L.; Behar, V.; Chorev, M.; Rosenblatt, M. and Bisello, A. Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves betaarrestin2. Real-time monitoring by fluorescence microscopy. J. Biol. Chem., 1999, 274, 29968-29975.
65. Vilardaga, J. P.; Krasel, C.; Chauvin, S.; Bambino, T.; Lohse, M. J. and Nissenson, R. A. Internalization determinants of the parathyroid hormone receptor differentially regulate betaarrestin/receptor association. J. Biol. Chem., 2002, 277, 8121-8129.
66. Dean, T.; Linglart, A.; Mahon, M. J.; Bastepe, M.; Juppner, H.; Potts, J. T., Jr. and Gardella, T. J. Mechanisms of ligand binding tothe parathyroid hormone (PTH)/PTH-related protein eceptor: Selectivity of a modified PTH(1-15) radioligand for G{alpha}Scoupled receptor conformations. Mol. Endo., 2006, 20, 931-943.
67. Jouishomme, H.; Whitfield, J. F.; Gagnon, L.; MacLean, S.; Isaacs, R.; Chakravarthy, B.; Durkin, J.; Neugebauer, W.; Willick, G. and Rixon, R. H. Further definition of the protein kinase C activation domain of the parathyroid hormone. J. Bon. Min. Res., 1994, 9, 943-949.
68. Whitfield, J. F. and Morley, P. Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Tren. Pharmacol. Sci., 1995, 16, 382-386.
69. Jouishomme, H.; Whitfield, J. F.; Chakravarthy, B.; Durkin, J. P.; Gagnon, L.; Isaacs, R. J.; MacLean, S.; Neugebauer, W.; Willick, G. and Rixon, R. H. The protein kinase-C activation domain of the parathyroid hormone. Endocrinology, 1992, 130, 53-60.
70. Azarani, A.; Goltzman, D. and Orlowski, J. Structurally diverse Nterminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways. J. Biol. Chem., 1996, 271, 14931-14936.
71. Takasu, H.; Gardella, T. J.; Luck, M. D.; Potts, J. T. and Bringhurst, F. R. Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: Implications for design of signal-specific PTH ligands. Biochemistry, 1999, 38, 13453-13460.
72. Bisello, A.; Chorev, M.; Rosenblatt, M.; Monticelli, L.; Mierke, D.F. and Ferrari, S. L. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J. Biol. Chem., 2002, 277, 38524-38530.
73. Bisello, A.; Manen, D.; Pierroz, D. D.; Usdin, T. B.; Rizzoli, R. and Ferrari, S. L. Agonist-specific regulation of parathyroid hormone (PTH) receptor type 2 activity: Structural and functional analysis of PTH-and tuberoinfundibular peptide (TIP) 39-stimulated desensitization and internalization. Mol. Endo., 2004, 18, 1486-1498.
74. Gardella, T. J.; Luck, M. D.; Jensen, G. S.; Schipani, E.; Potts, J.T., Jr. and Juppner, H. Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology, 1996, 137, 3936-3941.
75. Bouxsein, M. L.; Pierroz, D. D.; Glatt, V.; Goddard, D. S.; Cavat, F.; Rizzoli, R. and Ferrari, S. L. Beta-arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J. Bon. Min. Res., 2005, 20, 635-643.
76. Ferrari, S. L.; Pierroz, D. D.; Glatt, V.; Goddard, D. S.; Bianchi, E. N.; Lin, F. T.; Manen, D. and Bouxsein, M. L. Bone response to intermittent parathyroid hormone is altered in mice null for beta-Arrestin2. Endocrinology, 2005, 146, 1854-1862.
77. Pierroz, D. D.; Rufo, A.; Bianchi, E. N.; Glatt, V.; Capulli, M.; Rucci, N.; Cavat, F.; Rizzoli, R.; Teti, A.; Bouxsein, M. L. and Ferrari, S. L. Beta-arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J. Bon. Min. Res., 2009, 24, 775-784.
78. Pi, M.; Oakley, R. H.; Gesty-Palmer, D.; Cruickshank, R. D.; Spurney, R. F.; Luttrell, L. M. and Quarles, L. D. {Beta}-arrestinand G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol. Endo., 2005, 19, 1078-1087.
79. Kohout, T. A.; Lin, F. S.; Perry, S. J.; Conner, D. A. and Lefkowitz, R. J. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl. Acad. Sci. USA., 2001, 98, 1601-6.
80. Bohn, L. M.; Lefkowitz, R. J.; Gainetdinov, R. R.; Peppel, K.; Caron, M. G. and Lin, F. T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science, 1999, 286, 2495-8.